The Barchart Chart of the Day belongs to the biomedical company Denali Therapeutics (NASDAQ: DNLI). Since there isn't a lot of good news in the market today I thought I'd see how many stocks hit new All-Time Highs. At 3 PM today there were only 8! I sorted that list by the most frequent number of new highs in the last month then used the Flipchart feature to find a chart with consistent appreciation.  Since the Trend Spotter signaled a buy on 10/27 the stock was up .86%.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor-interacting serine/threonine-protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers are shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart technical indicators:

• 100% technical buy signal
• 174.60+ Weighted Alpha
• 194.90% gain in the last year
• Trend Spotter buy signal
• Above its 20, 50, and 100 day moving averages
• 10 new highs and up 31.19% in the last month
• Relative Strength Index 69.95% 
• Technical support level at 43.33
• Recently traded at 46.63 with a 50 day moving average of 36.97

Fundamental factors:

• Market Cap $4.86 billion
• Revenue expected to grow 1,529.20% this year
• Earnings estimated to increase 166.70% this year
• Wall Street analysts issued 5 strong buy, 1 buy, and 4 hold recommendations on the stock
• The individual investors following the stock on Motley Fool voted 6 to 3 that the stock will beat the market
• 3,240 investors are monitoring the stock on Seeking Alpha